

YOUR TRADITION. YOUR SOURCE.

**FOR IMMEDIATE RELEASE**

**HERITAGE INTRODUCES HYDROCHLOROTHIAZIDE TABLETS**

Edison, New Jersey, October 29, 2007. Heritage Pharmaceuticals Inc. announced the immediate availability of Hydrochlorothiazide (HCTZ) Oral Tablets in 25mg and 50mg strengths. Heritage received acceptance of its site transfer from the U.S. Food and Drug Administration for its approved, AB Rated Abbreviated New Drug Application (ANDA) for both strengths and will begin shipping immediately.

HCTZ Tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. HCTZ is also indicated in the management of hypertension. HCTZ had U.S. generic sales of approximately \$34 million for the 12-month period ending Dec. 31, 2006 according to IMS Health.

Heritage Pharmaceuticals Inc. is an emerging generic pharmaceutical company engaged in the acquisition, licensing, sale, marketing and distribution of generic pharmaceutical products for the global prescription drug markets. Commenting on the launch, President & CEO, Jeffrey Glazer, stated, "HCTZ represents our fourth product launch of the year in support of commercializing our acquired generic product line with strategic manufacturing partners. The addition of HCTZ to our product line increases our portfolio bandwidth as we continue our tradition of premier quality, value and service in generics."

***Contact:***

Kon Ostaficiuk

*Vice President of Sales & Marketing*

Heritage Pharmaceuticals Inc.

Toll free at: +1-866.901.1230

(T) 732.429.1000 ♦ (F) 732.429.1001

[sales@heritagepharma.com](mailto:sales@heritagepharma.com)

For more information about Heritage, please visit [www.heritagepharma.com](http://www.heritagepharma.com)